eli lilly glp 1 oral 𝗧𝗵𝗲 𝗼𝗿𝗮𝗹 𝗚𝗟𝗣-𝟭 𝗿𝗮𝗰𝗲 𝗷𝘂𝘀𝘁 𝗶𝗻𝘁𝗲𝗻𝘀𝗶𝗳𝗶𝗲𝗱 𝗔𝗻𝗱 𝗟𝗶𝗹𝗹𝘆 𝗹𝗮𝗻𝗱𝗲𝗱 𝗮 𝗱𝗶𝗿𝗲𝗰𝘁 𝗵𝗶𝘁 𝗼𝗻 𝗡𝗼𝘃𝗼. reported head-to-head trial data showing its GLP-1 candidate orforglipron outperformed Novo Nordisk's The Food and Drug Administration

Empowering you with personalized health data Your dashboard delivers comprehensive lab results and health insights to help you track and manage your wellness journey

FOXO4-DRI Key Research Facts Full name: FOXO4 D-Retro-Inverso peptide (FOXO4-DRI) Classification: Cell-penetrating senolytic peptide FOXO4/p53 protein-protein interaction inhibitor Design: D-retro-inverso isoform of FOXO4s p53-binding domain reversed sequence with all D-amino acids Binding target: p53 transactivation domain 2 (TAD2) displaces FOXO4 from the FOXO4-p53 complex Mechanism: FOXO4-DRI binds p53 TAD2 p53 nuclear exclusion p53 mitochondrial translocation BAX activation caspase-3 cleavage senescent cell-selective apoptosis Selectivity basis: FOXO4 is upregulated in senescent cells but expressed at low levels in most non-senescent adult cells selectivity is mechanistically conferred D-amino acid advantage: Proteolytic stability resistant to intracellular peptidases that would rapidly degrade equivalent L-amino acid sequences Structural characterisation: NMR structural models of FOXO4-DRI/p53TAD2 complex resolved (Nature Communications, 2025) confirms disordered-to-ordered transition upon binding Research cell types studied: IMR90 fibroblasts, TM3 Leydig cells, endothelial cells, chondrocytes, keloid fibroblasts, HCT116 cancer cells In vitro working concentration: 25 M used in multiple published studies for senescent cell apoptosis induction What Does FOXO4-DRI Do in Research

10mg vial

Sermorelin's signal is shorter and more closely mimics how your body would naturally release GHRH

Oral carnitine supplementation reduces body weight and insulin resistance in women with polycystic ovary syndrome: a randomized, doubleblind, placebocontrolled trial